Andrew Hess is an associate in the firm’s Business Law Department.

Mr. Hess represents private equity companies, biotechnology companies, pharmaceutical companies, and other entities in the healthcare space in a broad range of health care operational, regulatory, transactional, and compliance matters. Mr. Hess’ practice focuses on assisting these clients with analysis and due diligence related to compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the state and federal fraud and abuse laws (including the Anti-Kickback Statute, the Physician Self-Referral Law (the Stark law), and federal Civil Monetary Penalty provisions), and other laws and regulations governing the delivery of healthcare services.

Areas of Practice
Domaines D’Expertise





Mr. Hess’ recent experience includes:

  • Advised Absci Corporation, an AI-powered synthetic biology company that is unlocking the potential of proteins as the next generation of therapeutics, in its $230 million initial public offering. 
  • Advised underwriters in Rapid Micro Biosystems’ (a life sciences technology company providing automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products) $158.4 million initial public offering. 
  • Advised Aldrich Capital Partners in its acquisition of Rhythm Management Group Corp., a minority-owned provider of remote monitoring services for cardiac patients.
  • Advised Cano Health in its of acquisition of University Health Care, Inc., a provider of primary care to communities in South Florida.
  • Advised Monte Rosa Therapeutics, Inc., a clinical-stage developing a portfolio of novel small molecule precision medicines, on their $222.3 million initial public offering. 
  • Advised Goldman Sachs and Co. as lead underwriter in Valneva’s (a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases and COVID-19) $107.6 million initial public offering.
  • Advised Goldman Sachs and Co. and J.P. Morgan as underwriters in Privia Health Group, Inc.’s (a technology-driven, national physician enablement company) $131.7 million initial public offering. 
  • Advised Chiasma, Inc., a commercial stage biopharmaceutical company focused on developing and commercializing oral therapies for rare and serious chronic diseases, on its definitive agreement to be acquired by Amryt Pharma plc in an all-stock combination. 
  • Advised initial purchasers J.P. Morgan Securities LLC and SVB Leerink LLC on MannKind Corporation’s (a biopharmaceutical company focused on the development of therapeutic products for chronic conditions) Rule 144A offering of $230 million 2.50% Convertible Senior Notes Offering.
Professional Experience

Before attending law school, Mr. Hess interned in the Domestic Policy Council Office of Health Reform during the Obama administration. While at the White House, Mr. Hess focused on the implementation of the Affordable Care Act, including Medicaid expansion and the creation of the federally facilitated marketplace.

Mr. Hess then worked for a federal contractor assisting the Centers for Medicare & Medicaid Services (CMS) with the implementation of ICD-10. While serving as a healthcare consultant, Mr. Hess supported CMS by providing advice and creating systems that were critical to the successful implementation of ICD-10. These efforts included the program office’s risk management process, the facilitation of cooperation across the federal healthcare space (including operating divisions and staff divisions within the Department of Health and Human Services (HHS), as well as the Department of Veterans Affairs and the Military Health System), assisting in the successful navigation of multiple audits from the U.S. Government Accountability Office, and the planning and implementation of CMS’ ICD-10 Coordination Center, which aggregated claims data across the healthcare space for use by key decisionmakers (including the CMS administrator and secretary of HHS) and fielded questions from the public regarding the implementation of ICD-10 and its impact on billing and coding.

While in law school, Mr. Hess was a member of the Editorial Board of the Virginia Law and Business Review.

In The News









JD, 2019
The University of Virginia School of Law
(Dean’s Scholarship)
BA, Foreign Affairs, 2012
The University of Virginia



New York
Washington, D.C.
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique